Shares of Sarepta (SRPT -1.06%) were trading down 5%, after the company released its 62-week look at its Duchenne muscular dystrophy drug Eteplirsen. The company's 48-week look at the drug produced results that indicated the drug may revolutionize the way we treat the disease, as it not only slowed DMD's progression, it actually lengthened the distance patients were able to walk. The 62-week results were also good, but, perhaps, the market was expecting a miracle after what it saw at the 48-week mark. Sarepta stock jumped up 26% in November for a colossal 550% for the year.
S&P 500
5,939.30
-0.5%
-$31.51
DJI
42,319.74
-0.3%
-$108.00
NASDAQ
19,298.45
-0.8%
-$162.04
Bitcoin
103,926.00
-1.7%
-1,846.59
AAPL
$200.39
-1.2%
-$2.43
AMZN
$207.76
+0.3%
+$0.53
GOOG
$169.74
+0.2%
+$0.35
META
$683.71
-0.6%
-$4.24
MSFT
$467.07
+0.7%
+$3.20
NVDA
$139.88
-1.4%
-$2.04
TSLA
$285.20
-14.1%
-$46.85
Free Article
You're reading a free article with opinions that may differ from The Motley Fool's Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.